ClinicalTrials.gg
CompletedNCT05067634Updated Oct 16, 2026

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

A Phase 3 interventional study of Xcopri in Partial Epilepsy, sponsored by SK Life Science, Inc.. Completed at 35 sites in 7 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by SK Life Science, Inc. (part of SK Biopharmaceuticals) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Epilepsies, Partial by SK Biopharmaceuticals — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · SK Biopharmaceuticals.

Enrollment
10th of 12
154 · median 429
Started
2022
the only one that year
Phase 3
7 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Epilepsies, Partial by SK Biopharmaceuticals, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 13th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 13 studies in Epilepsies, Partial by SK Biopharmaceuticals is open now. The open studies under Epilepsies, Partial, anywhere →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Epilepsies, Partial by SK Biopharmaceuticals as a file.
02

Study summary

Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures

Read the detailed description

Secondary objectives:

  • To evaluate the efficacy of cenobamate tablets and suspension in pediatric subjects with partial onset (focal) seizures
  • To evaluate the pharmacokinetics of cenobamate tablets and suspension in pediatric subjects with partial onset seizures
  • To evaluate the PK/pharmacodynamics of cenobamate in pediatric subjects with partial onset (focal) seizures
  • Acceptability and palatability assessment (determined by a 5-point Hedonic Scale) of the oral formulation and the 12.5 mg tablets - Day 1, and Day 15
03

Conditions studied

  • Partial Epilepsy

Keywords

  • Partial-onset (focal) seizures
  • Pediatrics
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a diagnosis of epilepsy with partial-onset (focal) seizures (POS) with or without secondarily generalized seizures according to the International League Against Epilepsy's (ILAE) Classification of Epileptic Seizures. A diagnosis should have been established at least 12 months prior to Visit 1 (Screening) by clinical history and an electroencephalogram (EEG) that is consistent with the diagnosis; normal interictal EEGs will be allowed provided that the participant meets the other diagnosis criterion (i.e., clinical history)
  2. Male or female participant, from age 2 to less than 18 years at the time of /assent (dates including informed consent in YKP3089C039)
  3. Have a minimum weight of 10.0 kilograms (kg) (22.0 pounds [lb])
  4. Have had a brain imaging (e.g., magnetic resonance imaging [MRI] scan or computed tomography (CT) within 10 years before Visit 1 (Screening) that ruled out a progressive cause of epilepsy.
  5. For subjects new to Study YKP3089C040, participants must have had at least 1 POS seizure during the 28-day Baseline Period. Only simple POS with motor signs, complex POS, and complex POS with secondary generalization are counted toward this inclusion for POS
  6. Are currently being treated with stable doses of 1 to a maximum of 3 approved antiepileptic drugs (AEDs). Doses must be stable for at least 4 weeks before to Visit 1 (Screening). A vagal nerve stimulator [VNS] will not be counted as one of the 3 allowed AEDs but the settings should be stable for at least 4 weeks prior to Visit 1 (Screening).
  7. Investigator believes subject could benefit from new or continued exposure to study drug
  8. Subjects entering from study YKP3089C039 must continue to meet all of the inclusion criteria from the YKP3089C039 study
  9. Subjects receiving felbamate as a concomitant AED must meet the following criteria:

    1. Have a 12-month history of felbamate use and a history of a fixed dosing regimen for a minimum of 60 days prior to Visit 1 (Screening).
    2. No prior or known history of hepatotoxicity or hematologic disorder due to felbamate.
  10. Subjects following a ketogenic diet will be allowed as long as the diet has been stable for at least 30 days prior to Visit 1 (Screening) and will remain stable for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Females who are breastfeeding or pregnant at Screening or Baseline.
  2. Current or history of pseudo-seizures (psychogenic nonepileptic seizures) within approximately 2 years before Visit 1 (Screening).
  3. Have a history of status epilepticus that required hospitalization during the 6 months before Visit 1 (Screening).
  4. Have an unstable psychiatric diagnosis that may confound participants' ability to participate in the study or that may prevent completion of the protocol-specified tests (e.g., significant suicide risk, including suicidal behavior and ideation within 6 months before Visit 1 (Screening), current psychotic disorder, acute mania).
  5. Any suicidal ideation with intent, with or without a plan within 6 months before Visit 2 [i.e., answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) in participants aged 6 and above, if able].
  6. Are scheduled and/or confirmed to have epilepsy surgery within 6 months after Visit 1 (Screening); however, those who have previously documented "failed" epilepsy surgery will be allowed.
  7. Evidence of disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
  8. Presence of only nonmotor simple partial seizures or primary generalized epilepsies.
  9. Evidence of moderate or severe renal insufficiency as defined by estimated (eGFRs) of 31 to \< 60 "milliliters per minute (mL/min)" and \< 30 mL/min, respectively.
  10. Evidence of significant active hepatic disease. Stable elevation of liver enzymes, (ALT) and aspartate aminotransferase (AST) due to concomitant medication(s), will be allowed if they are less than 3 times the (ULN).
  11. Evidence of significant active hematological disease; white blood cell (WBC) count equal or less than 2500/µL (2.50 1E+09/liter [L]) or an equal or less than 1000/µL (1.00 1E+09/L).
  12. Subjects with Familial short syndrome.
  13. Clinically significant (ECG) abnormality, including prolonged corrected QT interval (QTc) defined as greater than 450 milliseconds (msec) or shortened corrected QT interval (QTc) defined as less than 340 msec.
  14. Have a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.
  15. Subject has a history of any serious drug-induced reaction (including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis, or DRESS) or any drug-related rash requiring hospitalization.
  16. History of AED-associated rash that involved conjunctiva or mucosae.
  17. History of more than one non-serious drug-related hypersensitivity reaction that required discontinuation of the medication.
  18. Concomitant use of vigabatrin. Participants who took vigabatrin in the past must be off vigabatrin for at least 5 months before Visit 1 (Screening) and with documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in a visual perimetry test.
  19. A history of intermittent use of rescue benzodiazepines (i.e., 1 to 2 doses over a 24-hour period is considered a 1-time rescue) more than once within the 30 days prior to Visit 1(Screening).
  20. A VNS implanted less than 5 months before Visit 1 (Screening) or changes in parameter less than 4 weeks before Visit 1 (or thereafter during the study).
  21. History of or a concomitant medical condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study or compromise the participant's ability to safely complete the study.
  22. Have participated in a study involving administration of an drug or device within 4 weeks before Visit 1 (Screening), or within approximately 5 half-lives of the previous investigational compound, whichever is longer.
  23. Participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
  24. For subjects new to Study YKP3089C040 previous exposure to cenobamate or sensitivity/allergy to components of the oral suspension.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    12 to < 18 year olds

    Drug: Xcopri

  • Experimental
    6 to <12 years old

    Drug: Xcopri

  • Experimental
    4 to <6 years old

    Drug: Xcopri

  • Experimental
    2 to <4 years old

    Drug: Xcopri

Interventions

  • DrugCenobamateStudies of CenobamateCenobamate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events and SAEs

    Summary statistics for clinical laboratory test results and vital signs; and physical examination, neurologic examination and electrocardiogram (ECG) finding.of age with partial-onset (focal) seizures

    Time frame: 3 Years

Secondary outcomes

  1. To collect plasma samples of cenobamate to support the evaluation of the pharmacokinetics of cenobamate tablets and suspension in pediatric subjects with partial onset (focal) seizures

    The area under the curve (AUC) of Xcopri after a single and multiple doses of Xcopri

    Time frame: 3 Years

  2. Acceptability and palatability assessment (determined by a 5-point Hedonic Scale) of the oral formulation and tablets

    Testing to determine how patients respond to the taste and route of Xcopri

    Time frame: 3 Years

07

Study locations

35 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Lucile Packard Children's Hospital Stanford
    Palo Alto, California 94304, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Clinical Integrative Research Center of Atlanta
    Sandy Springs, Georgia 30328, United States
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Northeast Regional Epilepsy Group
    Hackensack, New Jersey 07601, United States
  • Northeast Regional Epilepsy Group - Morristown
    Morristown, New Jersey 07960, United States
  • Boston Children's Health Physicians - Neurology at Hawthorne
    Hawthorne, New York 10532, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic Main Campus
    Cleveland, Ohio 44195, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Child Neurology Consultants of Austin
    Austin, Texas 78731, United States
  • Royal Children's Hospital Melbourne
    Parkville, Australia
  • Sydney Children's Hospital - Randwick
    Randwick, Australia
  • Children's Health Queensland Hospital and Health Service
    South Brisbane, Australia
  • Charite University Hospital
    Berlin, Germany
  • Bethesda Gyermekkorhaz
    Budapest, Hungary
  • Országos Klinikai Idegtudományi Intézet, Neurológiai Osztály
    Budapest, Hungary
  • Semmelweis University Dept. Of Paediatrics
    Budapest, Hungary
  • Servus Salvus Egészségügyi Szolgáltató Kft.
    Budapest, Hungary
  • Niepubliczny Zaklad Opieki Zdrowotnej - Centrum Neurologii Dzieciecej i Leczenia Padaczki
    Kielce, Poland
  • Centrum Medyczne Plejady
    Krakow, Poland
  • Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie
    Krakow, Poland
  • Chungbuk National University Hospital
    Cheonju, South Korea
  • Korea University Guro Hospital
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Severance Hospital
    Seoul, South Korea
  • SMG-SNU Boramae Medical Center
    Seoul, South Korea
  • Ajou University Hospital
    Suwon, South Korea
  • Hospital Sant Joan de Déu Barcelona
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebrón
    Barcelona, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2022 to primary completion in Oct 2026, 56 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Oct 5, 2021
StartActual
Jan 10, 2022
Primary completionActual
Oct 2, 2026was Nov 2026
CompletionActual
Oct 2, 2026was Nov 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
Nov 2026→Oct 2, 2026 (actual)
Oct 16, 2026
Study completion
Nov 2026→Oct 2, 2026 (actual)
Oct 16, 2026
Enrollment
140 (estimated)→154 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion Nov 2026→Oct 2, 2026 (now actual)
    Study completion Nov 2026→Oct 2, 2026 (now actual)
    Enrollment 140 (estimated)→154 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05067634
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Jan 10, 2022
Primary completion
Oct 2, 2026
Completion
Oct 2, 2026
Last update
Oct 16, 2026

Study contacts

Sunita Misra, MD
study director · SK Life Science, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenobamate

Start the discussion